Wasatch Advisors LP Has $20.49 Million Stock Position in TransMedics Group, Inc. $TMDX

Key Points

• Wasatch Advisors reduced its TransMedics Group stake by 10.9% in the second quarter, selling 37,710 shares. It still held 308,434 shares worth approximately $20.49 million, while institutional investors and hedge funds owned 99.67% of the stock.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings per share of $0.44 missed the $0.50 consensus forecast.
• Analyst sentiment is mixed: six analysts rate TMDX a Buy, six rate it Hold, and one rates it Sell. The stock has an average rating of Hold and an average price target of $124.18, despite several recent downgrades and target cuts.

Wasatch Advisors LP lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 10.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 308,434 shares of the company's stock after selling 37,710 shares during the period. Wasatch Advisors LP owned about 0.89% of TransMedics Group worth $20,486,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Harvest Fund Management Co. Ltd acquired a new position in shares of TransMedics Group during the 3rd quarter worth approximately $29,000. North Star Investment Management Corp. bought a new stake in shares of TransMedics Group during the 1st quarter worth approximately $30,000. Ascentis Independent Advisors acquired a new stake in shares of TransMedics Group in the 1st quarter valued at approximately $30,000. Allworth Financial LP boosted its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company's stock valued at $30,000 after buying an additional 113 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company's stock valued at $34,000 after buying an additional 83 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company's stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $87.02 on Thursday. The firm has a 50-day moving average of $74.90 and a 200-day moving average of $97.33. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The stock has a market cap of $3.01 billion, a PE ratio of 22.37 and a beta of 1.90. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business's quarterly revenue was up 20.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.92 EPS. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Zacks Research downgraded shares of TransMedics Group from a "hold" rating to a "strong sell" rating in a report on Monday, July 6th. Stifel Nicolaus lifted their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a research report on Thursday, June 18th. Oppenheimer lowered shares of TransMedics Group from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 6th. UBS Group dropped their target price on shares of TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a report on Wednesday, August 5th. Finally, Needham & Company LLC lowered their price target on TransMedics Group from $142.00 to $106.00 and set a "buy" rating on the stock in a research report on Monday, August 3rd. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $124.18.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source